Drugs / VRC-HIVADV027-00-VP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00472719 | Aug 2007 → Jul 2008 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00479999 | May 2007 → May 2014 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-HIVADV027-00-VP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00472719 ↗ |
| Known as | rAd35-EnvA | “The experimental vaccines in this study are the VRC-HIVADV027-00-VP (also called the rAd35-EnvA vaccine) and VRC-HIVADV038-00-VP (also called the rAd5-EnvA vaccine).” NCT00479999 ↗ |
| Modality | Vaccine | “adenoviral vector vaccine” NCT00472719 ↗ |
| Route | Other | “receive an injection of the adenoviral vector vaccine VRC-HIVADV027-00-VP” NCT00472719 ↗ |